Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBerkeley Eng Regulatory News (BKY)

Share Price Information for Berkeley Eng (BKY)

Share Price is delayed by 15 minutes
Get Live Data
24.50    0.00 (0.00%)
Bid:
24.00
Ask:
25.00
Spread: 1.00 (4.167%)
Market Cap: £109.34m
BKY Live PriceLast checked at - London Stock Exchange

Intraday Berkeley Eng Share Chart

Appendix 3B

18 Mar 2011 08:35

RNS Number : 2012D
Berkeley Resources Limited
18 March 2011
Β 

ο»Ώ

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

Β 

New issue announcement,

application for quotation of additional securities

and agreement

Β 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Β 

Β 

Name of entity

Berkeley Resources Limited

Β 

ABN

40 052 468 569

Β 

We (the entity) give ASX the following information.

Β 

Β 

Part 1 ‑ All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Β 

1

+Class of +securities issued or to be issued

Β 

Ordinary Shares

Β 

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

Β 

125

Β 

3

Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares

Β 

Β 

Β 

4

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

Β 

If the additional securities do not rank equally, please state:

Β·; the date from which they do

Β·; the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

Β·; the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Yes

Β 

Β 

Β 

5

Issue price or consideration

Β 

$0.75 each

Β 

Β 

Β 

Β 

6

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

Β 

Β 

Β 

Β 

Β 

Β 

Exercise of $0.75 Listed options expiring 15 May 2013

Β 

Β 

Β 

7

Dates of entering +securities into uncertificated holdings or despatch of certificates

Β 

Β 

17th March 2011

Β 

Β 

Number

+Class

8

Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)

Β 

Β 

Β 

174,298,273

11,989,428

Β 

Ordinary shares

$0.75 Options - 15/5/2013

Β 

Β 

Β 

Β 

Number

+Class

9

Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)

Β 

Β 

2,160,000

620,834

1,000,000

3,285,000

$1.86 Incentive Options - 5/8/2011

$1.00 Incentive Options - 19/6/2012

$1.25 Incentive Options - 1/12/2013

$1.35 Incentive Options - 18/6/2014

Β 

10

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Β 

Β 

Part 2 ‑ Bonus issue or pro rata issue

Β 

11

Is security holder approval required?

Β 

Β 

Β 

12

Is the issue renounceable or non-renounceable?

Β 

Β 

13

Ratio in which the +securities will be offered

Β 

Β 

14

+Class of +securities to which the offer relates

Β 

Β 

15

+Record date to determine entitlements

Β 

Β 

Β 

16

Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

Β 

Β 

17

Policy for deciding entitlements in relation to fractions

Β 

Β 

Β 

18

Names of countries in which the entity has +security holders who will not be sent new issue documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

Β 

Β 

19

Closing date for receipt of acceptances or renunciations

Β 

20

Names of any underwriters

Β 

Β 

Β 

Β 

21

Amount of any underwriting fee or commission

Β 

Β 

22

Names of any brokers to the issue

Β 

Β 

Β 

Β 

23

Fee or commission payable to the broker to the issue

Β 

Β 

24

Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders

Β 

Β 

25

If the issue is contingent on +security holders' approval, the date of the meeting

Β 

Β 

26

Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled

Β 

Β 

27

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

Β 

Β 

28

Date rights trading will begin (if applicable)

Β 

Β 

29

Date rights trading will end (if applicable)

Β 

Β 

Β 

Β 

30

How do +security holders sell their entitlements in full through a broker?

Β 

Β 

31

How do +security holders sell part of their entitlements through a broker and accept for the balance?

Β 

Β 

Β 

32

How do +security holders dispose of their entitlements (except by sale through a broker)?

Β 

Β 

33

+Despatch date

Β 

Β 

Β 

Β 

Β 

Part 3 ‑ Quotation of securities

You need only complete this section if you are applying for quotation of securities

Β 

34

Type of securities

(tick one)

Β 

(a)

Securities described in Part 1

Β 

(b)

All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Β 

Entities that have ticked box 34(a)

Β Additional securities forming a new class of securities

Β 

Β 

Tick to indicate you are providing the information or documents

Β 

35

If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

Β 

Β 

36

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

Β 

Β 

37

A copy of any trust deed for the additional +securities

Β 

Β 

Β 

Entities that have ticked box 34(b)

Β 

38

Number of securities for which +quotation is sought

Β 

Β 

Β 

Β 

Β 

39

Class of +securities for which quotation is sought

Β 

Β 

Β 

Β 

Β 

40

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

Β 

If the additional securities do not rank equally, please state:

Β·; the date from which they do

Β·; the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

Β·; the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Β 

Β 

Β 

Β 

41

Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

Β 

(if issued upon conversion of another security, clearly identify that other security)

Β 

Β 

Β 

Β 

Β 

Number

+Class

42

Number and +class of all +securities quoted on ASX (including the securities in clause 38)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Quotation agreement

Β 

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

Β 

2 We warrant the following to ASX.

Β 

Β·; The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

Β 

Β·; There is no reason why those +securities should not be granted +quotation.

Β 

Β·; An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

Β 

Β·; Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

Β 

Β·; If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

Β 

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

Β 

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Β 

Β 

Β 

Sam Middlemas 18 March 2011

Company Secretary

Β 

== == == == ==

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCEAPDPFDLFEEF
Date   Source Headline
27th Sep 20199:04 amRNSNotice of AGM
26th Sep 20197:55 amRNSAnnual report to shareholders
14th Aug 20199:31 amRNSHolding(s) in Company
31st Jul 20197:00 amRNSQuarterly Report June 2019
12th Jul 20198:00 amRNSFinal Director's Interest Notice
11th Jul 20197:00 amRNSStrategy and Management Changes
4th Jul 20197:55 amRNSDirector/PDMR Shareholding
1st Jul 20196:00 pmRNSHolding(s) in Company
25th Jun 20197:00 amRNSDrill programme for critical battery and EV metals
14th Jun 20197:55 amRNSIssue of shares and Appendix 3B
11th Jun 201911:05 amRNSSecond Price Monitoring Extn
11th Jun 201911:00 amRNSPrice Monitoring Extension
11th Jun 20197:00 amRNSElection result and award of three licences
28th May 20199:05 amRNSSecond Price Monitoring Extn
28th May 20199:00 amRNSPrice Monitoring Extension
28th May 20197:00 amRNSASX Response to Price and Volume Query
24th Apr 20197:55 amRNSQuarterly Report March 2019
8th Apr 20197:00 amRNSRecent Spanish Media Reports
11th Mar 20197:00 amRNSHalf-year Report
23rd Jan 201911:06 amRNSSecond Price Monitoring Extn
23rd Jan 201911:00 amRNSPrice Monitoring Extension
23rd Jan 20197:00 amRNSQuarterly Report December 2018
17th Jan 20194:40 pmRNSSecond Price Monitoring Extn
17th Jan 20194:35 pmRNSPrice Monitoring Extension
14th Jan 20192:06 pmRNSSecond Price Monitoring Extn
14th Jan 20192:01 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20197:00 amRNSBerkeley notes recent Spanish media reports
10th Jan 20194:35 pmRNSPrice Monitoring Extension
7th Jan 20197:59 amRNSASX Response to Price and Volume Query
4th Jan 20194:41 pmRNSSecond Price Monitoring Extn
4th Jan 20194:36 pmRNSPrice Monitoring Extension
4th Jan 201911:00 amRNSPrice Monitoring Extension
4th Jan 20197:55 amRNSChange of Director's Interest Notice x2
2nd Jan 20194:40 pmRNSSecond Price Monitoring Extn
2nd Jan 20194:35 pmRNSPrice Monitoring Extension
28th Dec 20187:59 amRNSReport on Payments to Govts
24th Dec 20187:55 amRNSHolding(s) in Company
20th Dec 20187:55 amRNSHolding(s) in Company
17th Dec 20187:55 amRNSHolding(s) in Company
30th Nov 20187:00 amRNSIssue of Incentive Performance Rights
22nd Nov 20187:32 amRNSResult of AGM
9th Nov 20188:00 amRNSChange of interests of substantial holder
29th Oct 20187:00 amRNSResponse to recent media reports
19th Oct 20187:00 amRNSNotice of AGM
18th Oct 20182:00 pmRNSPrice Monitoring Extension
17th Oct 20189:28 amRNSBerkeley responds to Spanish media reports
17th Oct 20189:06 amRNSSecond Price Monitoring Extn
17th Oct 20189:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.